Entity

Time filter

Source Type


Kumar P.,Hamdard University | Bhandari U.,Hamdard University | Jamadagni S.,National Research Institute of Ayurvedic Drug Development
BioMed Research International | Year: 2014

This study investigated the inhibitory effect of aqueous extract of Trigonella foenum-graecum seeds (AqE-TFG) on fat accumulation and dyslipidemia in high fat diet- (HFD-) induced obese rats. Female Wistar rats were fed with HFD ad libitum, and the rats on HFD were treated orally with AqE-TFG or orlistat ((HFD for 28 days + AqE-TFG (0.5 and 1.0 g/kg) or orlistat (10 mg/kg) from day 8 to 28), respectively. Treatment with AqE-TFG produced significant reduction in body weight gain, body mass index (BMI), white adipose tissue (WAT) weights, blood glucose, serum insulin, lipids, leptin, lipase, and apolipoprotein-B levels and elevation in adiponectin levels. AqE-TFG improved serum aspartate amino transferase (AST), alanine amino transferase (ALT), and lactate dehydrogenase (LDH) levels. AqE-TFG treatment reduced the hepatic and cardiac thiobarbituric acid reactive substances (TBARS) and elevated the antioxidant enzyme (glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT)) levels. In addition, liver and uterine WAT lipogenic enzyme (fatty acid synthetase (FAS) and glucose-6-phosphate dehydrogenase (G6PD)) activities were restored towards normal levels. These findings demonstrated the preventive effect of AqE-TFG on fat accumulation and dyslipidemia, due to inhibition of impaired lipid digestion and absorption, in addition to improvement in glucose and lipid metabolism, enhancement of insulin sensitivity, increased antioxidant defense, and downregulation of lipogenic enzymes. © 2014 Parveen Kumar et al. Source


Vijay Simha G.,National Institute of Ayurvedic Pharmaceutical Research | Kumar M.A.,National Institute of Ayurvedic Pharmaceutical Research | Rajesh S.,National Institute of Ayurvedic Pharmaceutical Research | Panda P.,National Research Institute of Ayurvedic Drug Development | Rao M.M.,Ayurveda Central Research Institute
Research Journal of Pharmacy and Technology | Year: 2012

Darbha (Imperata cylindrica (Linn.) Beauv) is commonly known as Cogon Grass and used in Ayurveda for the treatment of various urinary disorders. The plant belongs to the family Poaceae. It is a tufted, perennial grass with hard, creeping roots and it reaches a height of 0.6-1.5 m. It is found in hotter parts of India, both in plains and hills. It is found in all continents and is known as one of the ten worst weeds. It is an important drug of "Trinpanchmool". It is a reputed drug mentioned in the ancient books of Ayurveda, used extensively for the treatment of various ailments viz. urinary calculi, retention of urine, diabetes, cardiac disorder, gout, common cough and cold, inflammation, anaemia, etc. It also acts as aphrodisiac and rejuvenator. It is also used in traditional Chinese medicine. The drug contains five triterpenoids viz. cylindrin, arundorin, ferneon, isoburneol and simiarenol. The important Ayurvedic formulations of Darbha are Brahma Rasayana, Sukumara Ghrita, Karpuradyarka, Trikantaka Ghrita, Trinapanchamool kwath, Kushavaleha, Kushadhya ghrita etc. The root of this plant exhibited a set of diagnostic characters, which will help to identify the drug in dried condition. The present study attempts to investigate Phytochemical, Pharmacognostical and Physico-chemical parameters like pH, Loss on drying at 105°C, Water soluble extract, Alcohol soluble extract, Total Ash and Acid insoluble ash etc. These parameters will be useful in authentication and identification of the adulterants and quality control of raw drug of Imperata cylindrica (Linn.) Beauv. © RJPT All right reserved. Source


Debnath P.K.,National Research Institute of Ayurvedic Drug Development | Chattopadhyay J.,Rajiv Gandhi Memorial Ayurvedic College and Hospital | Mitra A.,National Research Institute of Ayurvedic Drug Development | Adhikari A.,R G Kar Medical College | And 3 more authors.
Journal of Ayurveda and Integrative Medicine | Year: 2012

Background: Pulmonary tuberculosis (PTB) is an age old disease described in Vedic Medicine as ′Yakshma′. Later on, in Ayurveda it earned a prefix and found way into mythology as ′Rajayakshma′. After the discovery of streptomycin, the therapeutic management of PTB received a major breakthrough. The treatment module changed remarkably with the formulation of newer anti-tubercular drugs (ATD) with appreciable success. Recent resurgence of PTB in developed countries like United States posed a threat to the medical community due to resistant strains. Consequently, WHO looked toward traditional medicine. Literature reveals that Ayurvedic treatment of PTB was in vogue in India before the introduction of ATD with limited success. Records show that 2766 patients of PTB were treated with Ayurvedic drugs in a tertiary care hospital in Kolkata in the year 1933-1947. Objectives: To evaluate the toxicity reduction and early restoration by adjunct therapy of Ayurvedic drugs by increasing the bio-availability of ATDs. Materials and Methods: In the present study, treatment response of 99 patients treated with ATD as an adjunct with Aswagandha (Withania somnifera) and a multi-herbal formulation described in Chikitsa-sthana of Charaka samhita i.e. Chyawanprash were investigated. Hematological profile, sputum bacterial load count, immunoglobulin IgA and IgM, blood sugar, liver function test, serum creatinine were the assessed parameters besides blood isoniazid and pyrazinamide, repeated after 28 days of treatment. Results: The symptoms abated, body weight showed improvement, ESR values were normal, there was appreciable change in IgA and IgM patterns and significantly increased bioavailability of isoniazid and pyrazinamide were recorded. Conclusion: This innovative clinical study coupled with empowered research may turn out to be promising in finding a solution for the treatment of PTB. Source


Harwansh R.K.,Jadavpur University | Mukherjee K.,Jadavpur University | Bhadra S.,Jadavpur University | Kar A.,Jadavpur University | And 3 more authors.
Journal of Ethnopharmacology | Year: 2014

Ethnopharmacological relevance Trikatu is a very well known 'Rasayana' in Ayurveda and widely used as a polyherbal ayurvedic formulation in India. It consists of three well known plants, viz.; Piper longum (PL), Piper nigrum (PN) and Zingiber officinale (ZO) in equal ratio. Trikatu has been prescribed for cough, cold, fever, asthma, respiratory problems and improvement of digestive disorders. The aim of the present study was to investigate the effect of individual ingredients of trikatu namely PL, PN, and ZO and formulations [Marketed formulation (MF) and laboratory formulation (LF)] on drug metabolizing enzymes (CYP3A4 and CYP2D6), to assess its herb-drug interaction potential through cytochrome P450 inhibition assays. Further this work was aimed to develop an RP-HPLC method for the identification and quantification of piperine and 6-gingerol in the crude drug trikatu. Materials and methods Enzyme inhibition effect of LF, MF, PL, PN and ZO was explored through CYP450-CO complex assay using rat liver microsomes (RLM) and a fluorescence screening method using individual isoenzymes (CYP3A4 and CYP2D6). The RP-HPLC method was developed for the identification and quantification of piperine and 6-gingerol in LF, MF and individual plant materials at the concentration of 1 mg/mL. Results RP-HPLC analysis confirmed the presence of piperine and 6-gingerol in LF and MF [Piperine: 7.89±2.12% (w/w) (MF), 6.70±2.13% (w/w) (LF)]; [6-gingerol: 5.3±1.21% (w/w) (MF), 4.95±2.34% (w/w) (LF)]. Inhibitory potential of MF and LF in CYP450-CO complex assay was found to be 37.54±3.12% (MF) and 35.12±2.31% (LF) and against CYP2D6 and CYP3A4 was estimated to be IC50 251.30±3.98 and 245.23±1.92 μg/mL and IC50 225.50±1.02 and 223.254±0.92 μg/mL respectively. Conclusions Different concentrations of the trikatu formulation and its individual components showed significantly (p<0.001) less inhibitory activity on individual isoenzymes as compared to the positive control. The crude drug exhibited inhibitory potential against the CYP450 enzymes in a concentration dependent manner. Outcome of the present study demonstrated that trikatu has less interaction potential with drug metabolizing enzymes. © 2014 Elsevier Ireland Ltd. Source


Adhikari A.,R G Kar Medical College | Biswas S.,N R S Medical College | Raman De R.,R G Kar Medical College | Mitra A.,National Research Institute of Ayurvedic Drug Development | And 2 more authors.
Indian Journal of Traditional Knowledge | Year: 2013

Upper respiratory tract disorders comprise 87.5% of total acute respiratory morbidity in children in India. This has become a major community health problem. The symptoms are often self limiting and many a time caused by viruses, however, recurrent attacks may lead to distinct morbidity. This study was conducted in hospital outpatient department on children who have been attending at frequent interval with complaints of sore throat, pharyngitis, tonsillitis. They were administered Imunomet syrup or tablet for a period of 8 weeks. At the end of the treatment, about 84% patients responded well to treatment and 16% patients had fair response to treatment. None of the patients showed any adverse reaction to treatment. The syrup was found to be palatable. Source

Discover hidden collaborations